Preview Mode Links will not work in preview mode

Evidence Based Medicine presented by InpharmD™

Feb 22, 2022

A phase 3, double-blind, randomized, placebo-controlled trial conducted to show superiority of SER-109 in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment. 

Feb 11, 2022

A retrospective study conducted to assess for any decrease in mortality associated with the use of the BNT162b2 (BioNTech, Pfizer  vaccine) booster.